Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment

Viktoria Blumenberg, Benjamin R. Puliafito, Charlotte E Graham, Mark B. Leick, Md Raihan Chowdhury, Maxx King, Deshea L. Harris, Noopur S. Raje, Andrew R. Branagan, Andrew J. Yee, Diana D. Cirstea, Kathleen M.E. Gallagher, Jörg Dietrich, Marcela V. Maus, Matthew J. Frigault

Blood blood.2024028172.

https://doi.org/10.1182/blood.2024028172

Published: 2025

Includes: Supplemental data

Journal Articles

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma

Loredana Santo, Janani Ramachandran, Diana D Cirstea, Homare Eda, Neeharika Nemani, Teru Hideshima, Chauhan Dharminder, Dennis Huszar, PhD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2014) 124 (21): 5726.

https://doi.org/10.1182/blood.V124.21.5726.5726

Published: 2014

Journal Articles

Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma

Rikio Suzuki, MD, PhD, Teru Hideshima, MD, PhD, Shuichi Ohkubo, PhD, Naoya Mimura, MD, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Shohei Kikuchi, MD, PhD, Diana D. Cirstea, Francesca Cottini, MD, Dharminder Chauhan, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Teruhiro Utsugi, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 4429.

https://doi.org/10.1182/blood.V122.21.4429.4429

Published: 2013

Journal Articles

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Yuko Mishima, Loredana Santo, Diana D. Cirstea, Homare Eda, Neeharika Nemani, Shirin Arastu-Kapur, Ph.D, Christopher J. Kirk, Ph.D, Simon S Jones, PhD, Raje Noopur, MD

Blood (2013) 122 (21): 4431.

https://doi.org/10.1182/blood.V122.21.4431.4431

Published: 2013

Journal Articles

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

Homare Eda, Loredana Santo, Diana D Cirstea, Andrew J Yee, Tyler A Scullen, Neeharika Nemani, Yuko Mishima, Shirin Arastu-Kapur, Erica Evans, Juswinder Singh, Christopher J Kirk, William F Westlin, Noopur S Raje

Blood (2013) 122 (21): 682.

https://doi.org/10.1182/blood.V122.21.682.682

Published: 2013

Journal Articles

Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma

Blood (2012) 120 (21): 571.

https://doi.org/10.1182/blood.V120.21.571.571

Published: 2012

Journal Articles

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy

Tyler Scullen, Sonia Vallet, Loredana Santo, Mariateresa Fulciniti, PhD, Homare Eda, Diana D. Cirstea, MD, Kishan Patel, Andrew Yee, Anuj Mahindra, MD, Noopur Raje, MD

Blood (2012) 120 (21): 1871.

https://doi.org/10.1182/blood.V120.21.1871.1871

Published: 2012

Journal Articles

Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,

Andrew J. Yee, MD, Anuj K. Mahindra, MD, Paul G. Richardson, MD, Diana D. Cirstea, MD, Tyler A. Scullen, BA, Scott J. Rodig, MD, PhD, Teru Hideshima, MD, PhD, Parameswaran Hari, MBBS, MD, MRCP, Jacob P. Laubach, MD, Irene M. Ghobrial, MD, Robert Schlossman, MD, Nikhil C. Munshi, MD, Edie A. Weller, PhD, Kenneth C. Anderson, MD, Noopur S. Raje, MD

Blood (2011) 118 (21): 3966.

https://doi.org/10.1182/blood.V118.21.3966.3966

Published: 2011

Journal Articles

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Noopur S. Raje, MD

Blood (2011) 118 (21): 1819.

https://doi.org/10.1182/blood.V118.21.1819.1819

Published: 2011

Journal Articles

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)

Claire Fabre, MD, PhD, Naoya Mimura, MD, PhD, Kathryn Bobb, MS, Gullu Gorgun, PhD, Diana D. Cirstea, MD, Yiguo Hu, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Jie Zhang, PhD, Jeffrey Meshulam, BS, Constantine S. Mitsiades, MD, PhD, Paul G. Richardson, MD, Teru Hideshima, MD, PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 2902.

https://doi.org/10.1182/blood.V118.21.2902.2902

Published: 2011

Journal Articles

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Walter C Ogier, Diana D. Cirstea, MD, Scott Rodig, MD, PhD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Miriam Canavese, PhD, James E. Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2912.

https://doi.org/10.1182/blood.V118.21.2912.2912

Published: 2011

Journal Articles

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Homare Eda, MD, PhD, Loredana Santo, MD, Diana D. Cirstea, MD, Samantha Pozzi, MD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Sonia Vallet, MD, Erica Evans, PhD, Juswinder Singh, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2882.

https://doi.org/10.1182/blood.V118.21.2882.2882

Published: 2011

Journal Articles

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Blood (2011) 118 (21): 133.

https://doi.org/10.1182/blood.V118.21.133.133

Published: 2011

NARROW

Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma

Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy

Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only